Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront...
China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront...
China-based Everest Medicines (HKG: 1952) has announced that it has received a full upfront payment...
China-based LBX Pharmacy has entered into a partnership with US-based Gilead Sciences, Inc (NASDAQ: GILD)....
US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial...
Cowell Health has announced a partnership with US-based Gilead Sciences, Inc., (NASDAQ: GILD) aimed at...
China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...
On September 17, an HIV precision medicine standardization project was initiated in Beijing. The project,...
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...
US pharmaceutical major Gilead Sciences Inc. (NASDAQ: GILD) today announced an agreement with Everest Medicines...